ArticleJapanese journal of ophthalmology
Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children.
Article in Japanese journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.Japanese journal of ophthalmology · 2012Trial
- Clinical and epidemiological profiles of vernal keratoconjunctivitis in a tertiary care setting: Association of disease pattern with recurrent attacks.Indian journal of ophthalmology · 2026Observational
- Evaluation of a new classification system for measuring the progression of ocular cystinosis: an analysis of 64 patients.The British journal of ophthalmology · 2025Article
- Ocular Surface Inflammatory Disorders (OSID): A Collective of Systemic Etiologies Which Cause or Amplify Dry Eye Syndrome.Frontiers in medicine · 2022Article
- Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Systemic diseases and the cornea.Experimental eye research · 2021Review
- Latest Clinical Approaches in the Ocular Management of Cystinosis: A Review of Current Practice and Opinion from the Ophthalmology Cystinosis Forum.Ophthalmology and therapy · 2018Review
- Tear Ferning Test and Pathological Effects on Ocular Surface before and after Topical Cyclosporine in Vernal Keratoconjunctivitis Patients.Journal of ophthalmology · 2018Article
- Clinical Practice: A Proposed Standardized Ophthalmological Assessment for Patients with Cystinosis.Ophthalmology and therapy · 2017Review
- Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis.Singapore medical journal · 2016Article
- Systematic approach to managing vernal keratoconjunctivitis in clinical practice: Severity grading system and a treatment algorithm.Indian journal of ophthalmology · 2016Article
- Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management.Therapeutic advances in chronic disease · 2016Review
- Retrospective review on the use of topical cyclosporin a 0.05% for paediatric allergic conjunctivitis in Hong Kong Chinese.TheScientificWorldJournal · 2014Article
- Supratarsal injection of triamcinolone acetonide and childhood allergic keratoconjunctivitis.International ophthalmology · 2012Article
- Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children.Journal of ophthalmic & vision researchReview
- Long-term use of 0.003% tacrolimus suspension for treatment of vernal keratoconjunctivitis.Oman journal of ophthalmologyArticle
- Oral cyclosporine therapy for refractory severe vernal keratoconjunctivitis.Indian journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy of topical cyclosporin A 0.05% in managing the symptoms of severe vernal keratoconjunctivitis (VKC).
methodsFifty-four children with severe VKC were included in this study. All 54 patients were treated with topical cyclosporin A (CsA) 0.05% for 3 months. Ocular signs and symptoms were scored in all patients at entry and after 3 months. Conjunctival impression cytology specimens were examined on the day of enrollment and at the end of the treatment period.
resultsThe mean scores for severity of signs and symptoms significantly decreased after 3 months compared with those at entry (P<0.001). The density of inflammatory cells in the conjunctival impression cytology specimens decreased significantly. No side effects of the treatment with CsA 0.05% eyedrops were observed.
conclusionsTopical CsA 0.05% eyedrops were found to be safe and effective in the treatment of patients with VKC. Consistent with these results, topical CsA may efficiently reduce conjunctival inflammation in severe VKC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.